AR057869A1 - Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto - Google Patents
Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuestoInfo
- Publication number
- AR057869A1 AR057869A1 ARP060104440A ARP060104440A AR057869A1 AR 057869 A1 AR057869 A1 AR 057869A1 AR P060104440 A ARP060104440 A AR P060104440A AR P060104440 A ARP060104440 A AR P060104440A AR 057869 A1 AR057869 A1 AR 057869A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- haloalkyl
- alkoxy
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000027534 Emotional disease Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002996 emotional effect Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Composicion farmacéutica que lo comprende y su uso para la fabricacion de un medicamento util para tratar o prevenir una enfermedad o trastornos mediados por a modulacion de los canales de sodio con apertura por voltaje (ôvoltaje-gatedö), como ser depresion o un trastorno del estado emocional, trastorno bipolar o relacionado con sustancias. Procesos para preparar dichos compuestos de formula (1). Reivindicacion 1: Un compuesto cuaternario de alfa-aminocarboxiamida caracterizado porque es de formula (1), su sal farmacéuticamente aceptable, solvato o profármaco: en la que R1 y R2 son independientemente H, alquilo C1-6, o (cicloalquil C3-6)alquilo C1-6; o estos R1 y R2, junto con el N al que están unidos, pueden formar un anillo saturado no sustituido de 3, 4, 5 o 6 miembros; R3 es alquilo C1-6, haloalquilo C1-6, alquenilo C1-3, (alcoxi C1-3)alquilo C1-3, (haloalquil C1-3)alquilo C1-3 o (CH2)tOH; o estos R1 y R3, junto a los átomos interconectores, forman un anillo saturado o insaturado de 5 a 7, con la condicion de que solo hay un heteroátomo en el anillo, que debe ser N; X es C o N; n es 0, 1 o 2, en el que, cuando está presente, cada R4 se selecciona independientemente de la lista que consiste en alquilo C1-3, halogeno, ciano, haloalquilo C1-3, hidroxi, alcoxi C1-3 y haloalcoxi C1-3; q es 1 o 2; t es 1 o 2; cualquiera de R5 o R6 es -O-R7 o -OCH2R7, en el que el otro R5 o R6 es H o R4; y en el que R7 es un anillo de fenilo o un anillo heterocíclico aromático de 5 o 6 miembros (que contiene independientemente uno o más átomos de N, S u O), en el que el anillo de fenilo o el anillo heterocíclico está opcionalmente sustituido con uno o más grupos seleccionados independientemente de la lista que consiste en alquilo C1-3, halogeno, ciano, haloalquilo C1-3, hidroxi, alcoxi C1-3 y haloalcoxi C1-3.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520578A GB0520578D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0523030A GB0523030D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603897A GB0603897D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0609159A GB0609159D0 (en) | 2006-05-09 | 2006-05-09 | Novel Compounds |
| GB0618511A GB0618511D0 (en) | 2006-09-20 | 2006-09-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057869A1 true AR057869A1 (es) | 2007-12-26 |
Family
ID=37762326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104440A AR057869A1 (es) | 2005-10-10 | 2006-10-09 | Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7803833B2 (es) |
| EP (1) | EP1934176B1 (es) |
| JP (1) | JP5139306B2 (es) |
| KR (1) | KR20080059297A (es) |
| AR (1) | AR057869A1 (es) |
| AT (1) | ATE543797T1 (es) |
| AU (1) | AU2006301471A1 (es) |
| BR (1) | BRPI0617189A2 (es) |
| CA (1) | CA2625763A1 (es) |
| CR (1) | CR9926A (es) |
| EA (1) | EA200801068A1 (es) |
| ES (1) | ES2381686T3 (es) |
| IL (1) | IL190544A (es) |
| NO (1) | NO20082122L (es) |
| NZ (1) | NZ567030A (es) |
| PE (1) | PE20070495A1 (es) |
| TW (1) | TW200728258A (es) |
| WO (1) | WO2007042240A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| JP5139307B2 (ja) * | 2005-10-10 | 2013-02-06 | グラクソ グループ リミテッド | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
| GB0701366D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| EP2477964B1 (en) | 2009-09-14 | 2015-02-11 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| JP2011232320A (ja) * | 2009-10-01 | 2011-11-17 | Sony Corp | 生体内物質検出用プローブ、および該生体内物質検出用プローブを用いた生体内物質検出装置 |
| EP2681200A4 (en) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) * | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
| WO2016102967A1 (en) * | 2014-12-23 | 2016-06-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| US9624169B2 (en) | 2015-03-27 | 2017-04-18 | Scifluor Life Sciences, Inc. | Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds |
| MX2020003811A (es) | 2017-10-05 | 2021-01-15 | Biogen Inc | Proceso para preparar derivados de alfa-carboxamida pirrolidina. |
| SG11202002707VA (en) | 2017-10-10 | 2020-04-29 | Biogen Inc | Process for preparing spiro derivatives |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| KR20020015308A (ko) | 1999-03-26 | 2002-02-27 | 추후보정 | 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도 |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| PE20050077A1 (es) | 2002-09-20 | 2005-03-01 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil-eter |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| EP1615895A4 (en) | 2003-04-03 | 2007-11-07 | Merck & Co Inc | BIARYLSUBSTITUTED PYRAZOLE AS SODIUM CHANNEL BLOCKER |
| CN1805945A (zh) | 2003-04-18 | 2006-07-19 | 麦克公司 | 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑 |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| WO2006119390A1 (en) | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| US7858786B2 (en) | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
| EP1888549A2 (en) | 2005-05-19 | 2008-02-20 | Vertex Pharmaceuticals, Inc. | Biaryls useful as modulators of ion channels |
| KR20090112722A (ko) | 2007-01-24 | 2009-10-28 | 글락소 그룹 리미티드 | 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물 |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136996A patent/TW200728258A/zh unknown
- 2006-10-06 BR BRPI0617189-3A patent/BRPI0617189A2/pt not_active IP Right Cessation
- 2006-10-06 EP EP06806111A patent/EP1934176B1/en active Active
- 2006-10-06 AT AT06806111T patent/ATE543797T1/de active
- 2006-10-06 NZ NZ567030A patent/NZ567030A/en unknown
- 2006-10-06 US US11/570,564 patent/US7803833B2/en active Active
- 2006-10-06 PE PE2006001224A patent/PE20070495A1/es not_active Application Discontinuation
- 2006-10-06 JP JP2008534911A patent/JP5139306B2/ja not_active Expired - Fee Related
- 2006-10-06 AU AU2006301471A patent/AU2006301471A1/en not_active Abandoned
- 2006-10-06 CA CA002625763A patent/CA2625763A1/en not_active Abandoned
- 2006-10-06 EA EA200801068A patent/EA200801068A1/ru unknown
- 2006-10-06 WO PCT/EP2006/009732 patent/WO2007042240A1/en not_active Ceased
- 2006-10-06 KR KR1020087011273A patent/KR20080059297A/ko not_active Withdrawn
- 2006-10-06 ES ES06806111T patent/ES2381686T3/es active Active
- 2006-10-09 AR ARP060104440A patent/AR057869A1/es active IP Right Grant
-
2008
- 2008-03-31 IL IL190544A patent/IL190544A/en active IP Right Grant
- 2008-04-25 CR CR9926A patent/CR9926A/es not_active Application Discontinuation
- 2008-05-06 NO NO20082122A patent/NO20082122L/no not_active Application Discontinuation
-
2010
- 2010-08-04 US US12/850,330 patent/US8153623B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20070495A1 (es) | 2007-05-17 |
| US20100324022A1 (en) | 2010-12-23 |
| US7803833B2 (en) | 2010-09-28 |
| US20080293753A1 (en) | 2008-11-27 |
| IL190544A0 (en) | 2008-11-03 |
| EP1934176A1 (en) | 2008-06-25 |
| NO20082122L (no) | 2008-07-02 |
| AU2006301471A1 (en) | 2007-04-19 |
| BRPI0617189A2 (pt) | 2011-07-19 |
| JP2009514801A (ja) | 2009-04-09 |
| IL190544A (en) | 2013-06-27 |
| CR9926A (es) | 2008-07-29 |
| CA2625763A1 (en) | 2007-04-19 |
| KR20080059297A (ko) | 2008-06-26 |
| TW200728258A (en) | 2007-08-01 |
| ES2381686T3 (es) | 2012-05-30 |
| EP1934176B1 (en) | 2012-02-01 |
| JP5139306B2 (ja) | 2013-02-06 |
| NZ567030A (en) | 2011-03-31 |
| ATE543797T1 (de) | 2012-02-15 |
| US8153623B2 (en) | 2012-04-10 |
| EA200801068A1 (ru) | 2009-02-27 |
| WO2007042240A1 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057869A1 (es) | Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto | |
| AR060237A1 (es) | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. | |
| PE20252338A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion | |
| AR029222A1 (es) | Compuesto derivado de amida, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la proteinquinasa | |
| CR10250A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR061222A1 (es) | Derivados de 2-oxo-piridina, 2-oxo-quinolina y 2-oxo-isoquinolina, composiciones farmaceuticas que los comprenden y el uso de los mismos en medicamentos para tratar enfermedades mediadas por la scd. | |
| AR034858A1 (es) | Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20070854A1 (es) | Compuestos heterociclos como agonistas del receptor de acido nicotinico | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR033344A1 (es) | Compuestos derivados de benzofenonas como inhibidores de la transcriptasa inversa, su uso en la fabricacion de medicamentos, intermediarios y composiciones farmaceuticas | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR070266A1 (es) | Derivados de n-(2-amino-fenil)-amida, una composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento para el tratamiento del cancer. | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| PE20220167A1 (es) | COMPUESTOS PIPERIDINIL BICICLICOS FUSIONADOS Y RELACIONADOS COMO MODULADORES DEL RECEPTOR C5a | |
| AR067904A1 (es) | Derivados de piperazina-amida | |
| RU2009136996A (ru) | Трициклические соединения, которые можно использовать для лечения нарушений, связанных с анормальным уровнем содержания железа в организме | |
| AR068480A1 (es) | Compuesto de 4-heteroaril-piperidinil-n-substituido su uso para la preparacion de un medicamento util para el tratamiento de una afeccion en el que seria beneficioso el agonismo de un receptor muscarinico m1 y composicion farmaceutica que lo comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |